[i] Numbers indicate percent Yes unless otherwise indicated. Study period was from June 21 to July 18, 2001.

[ii] Clinical information or information for patients only.

[iii] USA 28, UK 14, FR 9, FIN 8, NL 8, CA 8, BEL 4, SW 3, GER 3, IS 2, AUS 1, DEN 1, IRL 1 IT 1, JP 1, NZ 1, SP 1.

[iv] Not including links to OMIM.

[v] 3D models, schematic models, protein maps, protein mutation maps, linkage, tissue distribution.

[vi] Phylogenetic tree, maps of interacting proteins, primer sequences, methods, comments and source of mutations, therapies.

[vii] Including one subscription to have access to the most recent data.

[viii] Other software include pdf, Filemaker Pro, excel, JAVA, UMD, MuStar, LINUX, mySQL, Mutation View, MUTbase.

[ix] Antonarakis et al. 1998.

[x] Linkage, Iocus, CpG, genotype, domain, reference, consequences, exon, amino acid change, sample source, detection methods, chromosomes, proband tumour type, nucleotide change, restriction site change, intragenic position, RNA change, keyword, accession number, OMIM number.

[xi] Data collected January 2002.